Lipid-lowering therapy with statins reduces microparticle shedding from endothelium, platelets and inflammatory cells

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Biochemistry

Background:

• Hyperlipidemia is a key factor in atherosclerosis development.
• Statins are primary treatments for lowering LDL-cholesterol and offer benefits beyond lipid reduction.
• Circulating microparticles (cMPs) signal vascular and inflammatory cell activation, potentially influencing disease progression, but statin effects on cMPs are debated.

Purpose of the Study:

• To investigate the impact of statin-based lipid-lowering treatment (LLT) on circulating microparticle (cMP) generation.
• To evaluate cMP levels in patients receiving statins compared to normocholesterolemic controls for primary atherosclerosis prevention.

Main Methods:

• A case-control study compared hypercholesterolemic patients on statin LLT (LLT+) with matched normocholesterolemic controls (LLT-).
• Circulating microparticles were quantified using flow cytometry with annexin-V and cell-specific markers.
• Analysis included markers of platelet activation (αIIbβ3-integrin), inflammatory cells (αM-integrin), and tissue factor.

Main Results:

• Patients on statin LLT (LLT+) exhibited significantly lower overall cMP numbers compared to controls (p<0.005).
• LLT+ patients showed reduced levels of cMPs derived from platelets, endothelial cells, and various leukocyte subsets.
• Statin treatment led to decreased expression of activation markers on cMPs, including platelet and inflammatory cell markers.

Conclusions:

• Statin therapy is associated with a significant reduction in circulating microparticles expressing markers of activated cells, even at similar cholesterol levels.
• These findings suggest that statins provide protective effects against vascular cell activation.
• The observed reduction in cMP shedding appears to be cumulative over years of statin use and is linked to cardiovascular risk reduction.